{"id":"NCT02417961","sponsor":"AstraZeneca","briefTitle":"Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home","officialTitle":"A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04-27","primaryCompletion":"2016-03-14","completion":"2016-03-14","firstPosted":"2015-04-16","resultsPosted":"2017-06-12","lastUpdate":"2018-05-23"},"enrollment":162,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"BIOLOGICAL","name":"Benralizumab","otherNames":[]}],"arms":[{"label":"Benralizumab 30 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to assess functionality, performance, and reliability of an accessorized pre-filled syringe (APFS) with benralizumab administered subcutaneously (SC) in an at-home setting reported by the patient or caregiver, and to confirm the safety and clinical benefit of benralizumab administration in asthma patients with severe asthma.","primaryOutcome":{"measure":"Number and Percentage of Patients/Caregivers Who Successfully Administered Benralizumab 30 mg Subcutaneously (SC) by Injection With an APFS at Home","timeFrame":"Week 12, Week 16, and Weeks 12 and 16","effectByArm":[{"arm":"Benra 30 mg","deltaMin":112,"sd":null}],"pValues":[{"comp":"OG000","p":null},{"comp":"OG000","p":null},{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":8},"locations":{"siteCount":23,"countries":["United States","Canada"]},"refs":{"pmids":["29670379"],"seeAlso":["http://doi.org/10.2147/JAA.S157762","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3529&filename=D3250C00029_Clinical%20Study%20Protocol_GREGALE%20-%20Redacted.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":116},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Sinusitis","Headache","Viral upper respiratory tract infection"]}}